CD39 and CD73 as promising therapeutic targets : what could be the limitations?

Detalhes bibliográficos
Autor(a) principal: Battastini, Ana Maria Oliveira
Data de Publicação: 2021
Outros Autores: Figueiró, Fabrício, Leal, Daniela Bitencourt Rosa, Doleski, Pedro Henrique, Schetinger, Maria Rosa Chitolina
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/221805
id UFRGS-2_06451e8b99649b7e785a043fc9beb22f
oai_identifier_str oai:www.lume.ufrgs.br:10183/221805
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Battastini, Ana Maria OliveiraFigueiró, FabrícioLeal, Daniela Bitencourt RosaDoleski, Pedro HenriqueSchetinger, Maria Rosa Chitolina2021-06-02T04:33:14Z20211663-9812http://hdl.handle.net/10183/221805001125538application/pdfengFrontiers in pharmacology. Lausanne. Vol. 12 (Mar. 2021), 633603, 5 p.5'-nucleotidaseNucleosideosNucleotídeosCD39CD73InhibitorsPurinergic systemTherapeutic approachLimitationsCD39 and CD73 as promising therapeutic targets : what could be the limitations?Estrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001125538.pdf.txt001125538.pdf.txtExtracted Texttext/plain34016http://www.lume.ufrgs.br/bitstream/10183/221805/2/001125538.pdf.txt47842d2d4fa323f81bf6e8e585a27d9aMD52ORIGINAL001125538.pdfTexto completo (inglês)application/pdf592863http://www.lume.ufrgs.br/bitstream/10183/221805/1/001125538.pdfe53c8a6003c6f4ff5da4ff9a2bd6d14cMD5110183/2218052021-06-13 04:30:16.753556oai:www.lume.ufrgs.br:10183/221805Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2021-06-13T07:30:16Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv CD39 and CD73 as promising therapeutic targets : what could be the limitations?
title CD39 and CD73 as promising therapeutic targets : what could be the limitations?
spellingShingle CD39 and CD73 as promising therapeutic targets : what could be the limitations?
Battastini, Ana Maria Oliveira
5'-nucleotidase
Nucleosideos
Nucleotídeos
CD39
CD73
Inhibitors
Purinergic system
Therapeutic approach
Limitations
title_short CD39 and CD73 as promising therapeutic targets : what could be the limitations?
title_full CD39 and CD73 as promising therapeutic targets : what could be the limitations?
title_fullStr CD39 and CD73 as promising therapeutic targets : what could be the limitations?
title_full_unstemmed CD39 and CD73 as promising therapeutic targets : what could be the limitations?
title_sort CD39 and CD73 as promising therapeutic targets : what could be the limitations?
author Battastini, Ana Maria Oliveira
author_facet Battastini, Ana Maria Oliveira
Figueiró, Fabrício
Leal, Daniela Bitencourt Rosa
Doleski, Pedro Henrique
Schetinger, Maria Rosa Chitolina
author_role author
author2 Figueiró, Fabrício
Leal, Daniela Bitencourt Rosa
Doleski, Pedro Henrique
Schetinger, Maria Rosa Chitolina
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Battastini, Ana Maria Oliveira
Figueiró, Fabrício
Leal, Daniela Bitencourt Rosa
Doleski, Pedro Henrique
Schetinger, Maria Rosa Chitolina
dc.subject.por.fl_str_mv 5'-nucleotidase
Nucleosideos
Nucleotídeos
topic 5'-nucleotidase
Nucleosideos
Nucleotídeos
CD39
CD73
Inhibitors
Purinergic system
Therapeutic approach
Limitations
dc.subject.eng.fl_str_mv CD39
CD73
Inhibitors
Purinergic system
Therapeutic approach
Limitations
publishDate 2021
dc.date.accessioned.fl_str_mv 2021-06-02T04:33:14Z
dc.date.issued.fl_str_mv 2021
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/221805
dc.identifier.issn.pt_BR.fl_str_mv 1663-9812
dc.identifier.nrb.pt_BR.fl_str_mv 001125538
identifier_str_mv 1663-9812
001125538
url http://hdl.handle.net/10183/221805
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Frontiers in pharmacology. Lausanne. Vol. 12 (Mar. 2021), 633603, 5 p.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/221805/2/001125538.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/221805/1/001125538.pdf
bitstream.checksum.fl_str_mv 47842d2d4fa323f81bf6e8e585a27d9a
e53c8a6003c6f4ff5da4ff9a2bd6d14c
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1801225019262500864

Registros relacionados